上市公司資料
 
上海復星醫藥(集團)股份有限公司 股票代號:  02196
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. 集團網址: http://www.fosunpharma.com
損益表
  2025/12
RMB(K$)
變動 2024/12
RMB(K$)
2023/12
RMB(K$)
營業額41,498,3251.438%40,909,87841,248,505
經營溢利/(虧損)3,188,00526.236%2,525,4421,092,059
特殊項目--------
攤佔聯營公司及共同控制公司溢利/(虧損)1,923,97917.042%1,643,8392,184,849
稅前溢利/(虧損)5,111,98422.611%4,169,2813,276,908
稅項(864,054)--(656,841)(369,504)
少數股東權益(877,368)--(742,554)(508,798)
股東應佔溢利/(虧損)3,370,56221.686%2,769,8862,398,606
 
淨利息收入/(支出)(964,847)--(1,058,705)(961,186)
折舊與攤銷3,847,99018.687%3,242,1463,202,753
董事酬金----21,28448,086
 
每股盈利/(虧損)(仙)127.00022.115%104.00090.000
每股派息(仙)39.00021.875%32.00027.000
 
派息比率(%)30.709%--30.769%30.000%
每股帳面資產淨值($)18.4513.859%17.76617.081
主要財務比率
  2025/12
RMB(K$)
變動 2024/12
RMB(K$)
2023/12
RMB(K$)
經營邊際利潤率(%)7.682%--6.173%2.648%
利息盈利率(x)5.040--3.9123.473
資產回報率(%)2.839%--2.400%2.175%
股東資金回報率(%)7.027%--5.965%5.320%

 

Copyright © 2026 ET Net Limited. All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.